For example, human-IL-2 linked to tumor-reactive mAbs such as hu14.18-IL-2, anti-CD20-IL-2, DI-Leu16-IL-2, and anti-CEA M5A-IL-2 have shown similar trends of stimulating an antibody-directed response against cancer, including testing for cancer therapy currently in clinical trials [15,24]. Here, CEACAM5 is linked to neoplasm.